Allosteric Modulation of Neuronal Nicotinic Acetylcholine Receptors
神经元烟碱乙酰胆碱受体的变构调节
基本信息
- 批准号:8812153
- 负责人:
- 金额:$ 41.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-30 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlzheimer&aposs DiseaseBasic ScienceBehaviorBindingBinding SitesBiochemistryChemicalsChemosensitizationCommunitiesCysteineDevelopmentDiseaseDisulfidesExtracellular DomainFaceFamilyFoundationsFutureGated Ion ChannelGoalsHeadHealthHumanHydrophobic InteractionsImpaired cognitionIndividualInterventionInvestigationIon ChannelLigand BindingLigandsMediatingModelingModificationMolecularMovementNeuronsNeuropharmacologyNeurophysiology - biologic functionNeurosciencesNicotine DependenceNicotinic ReceptorsParkinson DiseasePathway interactionsPatternPharmaceutical PreparationsPharmacologic SubstancePlayPoint MutationProcessPropertyProtein FamilyProteinsRelative (related person)ResearchRoleRouteScienceSignal TransductionSiteSpecificityStructureStructure-Activity RelationshipStudentsTestingTherapeuticThermodynamicsTrainingWorkanalogclinical applicationcohortcrosslinkdesigndrug developmentimprovedinnovationmutantnervous system disordernovelprogramsprotein structurepublic health relevancereceptorresearch studyvoltage clamp
项目摘要
DESCRIPTION (provided by applicant): We study allosteric modulation of neuronal nicotinic acetylcholine receptors (nAChRs). These ligand-gated ion channels are the seat of nicotine addiction and are implicated in a wide range of other neurological disorders. Allosteric modulation of nAChRs is growing in importance as it becomes better understood and as novel compounds with this pharmacological profile are identified. The binding sites for a class of model modulatory compounds, quite specific for one subtype of neuronal nAChR, are known, and some molecular determinants of transducing modulator binding information into channel activity have been identified. Building on this previous work, we now propose to further refine our understanding of the movement of one sub- structure involved in intra-molecular signal transduction and of the molecular determinants of modulator site specificity. In addition, questions about channel gating efficacy will be addressed in terms of the optimal number and arrangement of modulator sites relative to agonist sites and the role of hydrophobic residues in the extracellular domain core. These studies will employ pharmacological characterization of expressed receptors with point mutations or concatenated subunits by macroscopic voltage-clamp recordings, as well as chemical modification analyses. The project also includes a targeted structure-activity relationship study with new modulator analogues. In some cases, to support these primary aims, we will explore the modulation mechanisms further by single-channel recordings. Our work is innovative because we are challenging the paradigm of activation of nAChRs by occupying two agonist binding sites. We are studying a recently identified nAChR ligand binding site, and the work we propose stands to substantially strengthen the foundation for rational design of nAChR allosteric modulators, a drug class with possible clinical applications.
描述(由申请人提供):我们研究神经元烟碱乙酰胆碱受体(nAChR)的变构调节。这些配体门控离子通道是尼古丁成瘾的根源,并与多种其他神经系统疾病有关。随着 nAChR 的变构调节得到更好的理解以及具有这种药理学特征的新化合物的被发现,它变得越来越重要。一类模型调节化合物的结合位点(对神经元 nAChR 的一种亚型非常特异)是已知的,并且已经鉴定了将调节剂结合信息转导为通道活性的一些分子决定因素。在先前工作的基础上,我们现在建议进一步完善我们对分子内信号转导所涉及的一个子结构的运动以及调节剂位点特异性的分子决定因素的理解。此外,有关通道门控功效的问题将根据调节剂位点相对于激动剂位点的最佳数量和排列以及胞外域核心中疏水残基的作用来解决。这些研究将通过宏观电压钳记录以及化学修饰分析,对具有点突变或串联亚基的表达受体进行药理学表征。该项目还包括利用新的调节剂类似物进行有针对性的结构-活性关系研究。在某些情况下,为了支持这些主要目标,我们将通过单通道录音进一步探索调制机制。我们的工作具有创新性,因为我们正在通过占据两个激动剂结合位点来挑战 nAChR 激活的范式。我们正在研究最近发现的 nAChR 配体结合位点,我们建议的工作将大大加强合理设计 nAChR 变构调节剂的基础,nAChR 变构调节剂是一类具有可能临床应用的药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark M Levandoski其他文献
Mark M Levandoski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark M Levandoski', 18)}}的其他基金
Allosteric Potentiation of Neuronal Nicotinic Receptors
神经元烟碱受体的变构增强
- 批准号:
7940171 - 财政年份:2010
- 资助金额:
$ 41.47万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 41.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 41.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)